FY2026 Full year results
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report details FDA clearance and reimbursement for CT:VQ™, along with rapid adoption by leading U.S. academic medical centers and a distribution agreement with Philips. Financially, the company reported an increase in operating revenue and a substantial cash balance, positioning it well for future growth. The filing emphasizes the expansion of CT:VQ™ into international markets, including Europe and Australia, and partnerships with major pharmaceutical companies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- Azra AI and 4DMedical Partner to Bring Enterprise-Wide Lung Health Intelligence to Health Systems
- US Bill directs VA to adopt 4D lung imaging
- Pause in trade
- 4DMedical Receives TGA Approval for CT: VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
- 4DMedical receives TGA approval for CTVQ in Australia
Later from 4DMedical
All 4DMedical news releasesFollow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical